在MAPK抑制剂治疗期间通过ITCH增强PD-L1降解可抑制获得性耐药
在黑色素瘤中,MAPK抑制剂(MAPKi)治疗导致肿瘤表面PD-L1/L2积聚,可能逃避免疫并加速获得性耐药。本研究发现E3泛素连接酶ITCH可结合、泛素化并下调MAPKi处理的人黑色素瘤细胞表面的PD-L1/L2,促进T细胞活化;体内实验表明肿瘤细胞内在ITCH敲低加速免疫健全小鼠的获得性耐药,而ITCH过表达则抑制耐药,且小分子ITCH激活剂可在体内抑制获得性MAPKi耐药。
要点
- MAPKi治疗诱导肿瘤表面PD-L1/L2积聚,加速获得性耐药。
- ITCH泛素化并降解肿瘤表面PD-L1/L2,促进T细胞活化。
- 小分子ITCH激活剂在体内抑制获得性MAPKi耐药。
核心结论
- MAPKi诱导的PD-L1加速耐药,而降解PD-L1的ITCH激活剂可延长抗肿瘤反应。
研究设计与样本
- 研究使用人黑色素瘤细胞、免疫健全小鼠体内模型,涉及ITCH敲低与过表达、CD8+ T细胞清除及PD-L1过表达等实验。
主要发现
- ITCH可结合、泛素化并下调MAPKi处理的人黑色素瘤细胞表面的PD-L1/L2,促进T细胞活化。
- 体内MAPKi治疗期间,肿瘤细胞内在ITCH敲低诱导肿瘤表面PD-L1、减少瘤内细胞毒性CD8+ T细胞,并仅在免疫健全小鼠中加速获得性耐药。
- 肿瘤细胞内在ITCH过表达减少MAPKi诱导的PD-L1积聚、增加瘤内细胞毒性CD8+ T细胞,并在BrafV600MUT、NrasMUT或Nf1MUT黑色素瘤及KrasMUT驱动的癌症中抑制获得性耐药。
- CD8+ T细胞清除和肿瘤细胞内在PD-L1过表达消除了ITCH过表达的表型,支持体内ITCH-PD-L1-T细胞调控轴。
- 鉴定出一种小分子ITCH激活剂,可在体内抑制获得性MAPKi耐药。
临床怎么用
- 作者提出降解肿瘤细胞表面PD-L1和/或激活肿瘤内在ITCH作为克服MAPKi耐药的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: MAPK inhibitor (MAPKi) therapy in melanoma leads to the accumulation of tumor-surface PD-L1/L2, which may evade antitumor immunity and accelerate acquired resistance. Here, we discover that the E3 ligase ITCH binds, ubiquitinates, and downregulates tumor-surface PD-L1/L2 in MAPKi-treated human melanoma cells, thereby promoting T-cell activation. During MAPKi therapy in vivo, melanoma cell-intrinsic ITCH knockdown induced tumor-surface PD-L1, reduced intratumoral cytolytic CD8+ T cells, and accelerated acquired resistance only in immune-competent mice. Conversely, tumor cell-intrinsic ITCH overexpression reduced MAPKi-elicited PD-L1 accumulation, augmented intratumoral cytolytic CD8+ T cells, and suppressed acquired resistance in BrafV600MUT, NrasMUT, or Nf1MUT melanoma and KrasMUT-driven cancers. CD8+ T-cell depletion and tumor cell-intrinsic PD-L1 overexpression nullified the phenotype of ITCH overexpression, thereby supporting an in vivo ITCH-PD-L1-T-cell regulatory axis. Moreover, we identify a small-molecular ITCH activator that suppresses acquired MAPKi resistance in vivo. Thus, MAPKi-induced PD-L1 accelerates resistance, and a PD-L1-degrading ITCH activator prolongs antitumor response. SIGNIFICANCE: MAPKi induces tumor cell-surface PD-L1 accumulation, which promotes immune evasion and therapy resistance. ITCH degrades PD-L1, optimizing antitumor T-cell immunity. We propose degrading tumor cell-surface PD-L1 and/or activating tumor-intrinsic ITCH as strategies to overcome MAPKi resistance. This article is highlighted in the In This Issue feature, p. 1825.
引用
- Yang Z, Wang Y, Liu S, et al. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer Discov. 2022. PMID: 35638972. doi:10.1158/2159-8290.CD-21-1463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。